Cleveland BioLabs Inc. (CBLI, $6.40, $0.20, 3.2%) could benefit speculation that the government may call for a drug to treat exposure to radiation. The company expects to start human trials on its drug to protect good cells during cancer radiation this fall.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.